Predictors of anticoagulation in hospice patients with lung cancer

14Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

BACKGROUND: Guidelines recommend lifelong anticoagulation in patients with cancer and a history of thromboembolism, but the use of anticoagulation in hospice has not been described. A retrospective study of medication data was conducted to determine patterns of anticoagulant use and predictors of type of anticoagulant prescribed for hospice patients with lung cancer. METHODS: Medication data were evaluated for 16,896 hospice patients with lung cancer in 2006 to determine patient and hospice characteristics that predicted anticoagulant prescription. Independent predictors of warfarin versus low molecular weight heparin (LMWH) prescription were identified using a logistic regression model. RESULTS: One of every 11 patients was prescribed an anticoagulant, most commonly warfarin. Compared with patients prescribed LMWH, patients prescribed warfarin were older (71.6 vs 65.8 years, P

Cite

CITATION STYLE

APA

Holmes, H. M., Bain, K. T., Zalpour, A., Luo, R., Bruera, E., & Goodwin, J. S. (2010). Predictors of anticoagulation in hospice patients with lung cancer. Cancer, 116(20), 4817–4824. https://doi.org/10.1002/cncr.25284

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free